Industry News
CSL receives official warning from FDA
The US Food and Drug Administration has issued an official warning letter to CSL listing concerns about the manufacture of influenza vaccine, Afluria. [ + ]
AusBiotech supports research exemption in patent reform Bill
AusBiotech has welcomed the research exemption from patent infringement in Australia’s intellectual property reform bill introduced into Parliament today. [ + ]
BIO 2011 biotech profile: Mesoblast’s vision from the top
Mesoblast CEO, Professor Silviu Itescu , was instrumental in cutting the historic billion-dollar deal with Cephalon. He speaks to ALS about how he did it. [ + ]
BIO 2011 biotech profile: Mesoblast
Mesoblast has been making great strides in its stem cell technology over the past several years, and it all paid off with a game changing deal cut with US pharma Cephalon late last year. [ + ]
Top-performing Australian students strive for gold
The 23 talented students chosen to represent Australia at the UNESCO-sanctioned International Science and Mathematical Olympiads have received their team blazers at a ceremony in Parliament House, Canberra.
[ + ]R&D Tax Credit will boost small biotechs
The R&D Tax Credit will give a much needed boost to small cap biotechs, says Karen Sinclair, past president of LESANZ. [ + ]
Controversial biological and gene patent Bill delayed
The Senate has issued an extension until August for the hotly debated Patent Amendment (Human Genes and Biological Materials) Bill. [ + ]
New R&D tax credit will start in July
Australian companies will become more innovative and globally competitive thanks to the new R&D tax incentive.
[ + ]Deadly E. coli strain sequenced by HPA scientists
The deadly E. coli O104 strain found in Europe has been sequenced using 454 Life Sciences’ benchtop GS Junior sequencing system.
[ + ]R&D Tax Credit (finally) gets the go ahead
Crossbench support has paved the way for the beleaguered R&D Tax Credit to pass the Senate in the next session, coming into effect as of 1 July 2011. [ + ]
QRxPharma to file NDA within two months
After completing a phase III safety trial of analgesic MoxDuo IR QRxPharma (ASX: QRX) is winding up for its New Drug Application within two months time. [ + ]
BIO 2011 special report: The third wave of Australian biotechs
Following the successes of the last six months in Australian biotechnology, the question becomes: who’s next? [ + ]
Molecular diagnostics technology aids management of E. coli crisis
A new xTAG gastrointestinal pathogen panel has been used to triage patients suspected of having an E. coli infection at German Kliniken der Stadt Koln.
[ + ]BIO 2011 special report: Australian biotechnology comes of age
The Australian biotechnology industry has entered a new phase, with several high profile deals demonstrating the sector can truly deliver. Now attention is turning to what comes next. [ + ]
